Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Midatech Pharma stock

Learn how to easily invest in Midatech Pharma stock.

Midatech Pharma plc is a biotechnology business based in the US. Midatech Pharma shares (MTP) are listed on the NASDAQ and all prices are listed in US Dollars. Midatech Pharma employs 18 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Midatech Pharma

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – MTP – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Midatech Pharma stock price (NASDAQ: MTP)

Use our graph to track the performance of MTP stocks over time.

Midatech Pharma shares at a glance

Information last updated 2022-01-16.
Latest market close$1.13
52-week range$1.02 - $3.83
50-day moving average $1.36
200-day moving average $1.79
Wall St. target priceN/A
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-0.89

Buy Midatech Pharma shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
SoFi Invest
Stocks, ETFs, Cryptocurrency
Get one free stock worth up to $1,000
Open an account
A free way to invest in most equities.
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$0 per month
$10 of crypto
Open an account with access to crypto
A platform built for all kinds of traders and all styles of trading
Stocks, Options, ETFs, Cryptocurrency
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Stash Invest
Stocks, ETFs
$1 per month
Add at least $5 to your Invest account
Stash is more than an investment app. You’ll have access to tools that can help you become a confident investor.
Stocks, ETFs, Cryptocurrency
$0 per month
Download and sign up with; approved accounts receive a free stock slice worth up to $300, selected from 9 popular stocks.
Open an account
Commission-free trading in stocks and ETFs with a social networking twist.
Stocks, Options, ETFs
$0 per year
Get a free stock valued up to $3500
Open your Futu brokerage account via Moomoo
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Midatech Pharma stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Midatech Pharma price performance over time

Historical closes compared with the close of $1.13 from 2022-01-18

1 week (2022-01-12) -4.24%
1 month (2021-12-17) -7.38%
3 months (2021-10-19) -38.92%
6 months (2021-07-19) -38.59%
1 year (2021-01-19) -51.29%
2 years (2020-01-17) 25.56%
3 years (2019-01-18) 650.33%
5 years (2017-01-19) 2.9658

Midatech Pharma financials

Revenue TTM $576,000
Gross profit TTM $-3,985,000
Return on assets TTM -19.06%
Return on equity TTM -190.94%
Profit margin 0%
Book value $0.30
Market capitalisation $15.6 million

TTM: trailing 12 months

Midatech Pharma share dividends

We're not expecting Midatech Pharma to pay a dividend over the next 12 months.

Have Midatech Pharma's shares ever split?

Midatech Pharma's shares were split on a 1:5 basis on 2 March 2020. So if you had owned 5 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Midatech Pharma shares – just the quantity. However, indirectly, the new 400% higher share price could have impacted the market appetite for Midatech Pharma shares which in turn could have impacted Midatech Pharma's share price.

Midatech Pharma share price volatility

Over the last 12 months, Midatech Pharma's shares have ranged in value from as little as $1.015 up to $3.83. A popular way to gauge a stock's volatility is its "beta".

MTP.US volatility(beta: 1.58)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Midatech Pharma's is 1.5846. This would suggest that Midatech Pharma's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Midatech Pharma overview

Midatech Pharma plc focuses on the research and development of oncology and rare disease products in the United Kingdom, rest of Europe, and internationally. The company is developing MTX110, a direct delivery treatment for diffuse intrinsic pontine glioma, medulloblastomas, and glioblastoma multiforme; MTX114, an immuno-suppressant for topical application in psoriasis; and MTD211 and MTD219 for central nervous system and transplant anti-rejection indications. It also offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release drug delivery; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. The company was founded in 2000 and is headquartered in Cardiff, the United Kingdom. .

Frequently asked questions

What percentage of Midatech Pharma is owned by insiders or institutions?
Currently 0.135% of Midatech Pharma shares are held by insiders and 5.663% by institutions.
How many people work for Midatech Pharma?
Latest data suggests 18 work at Midatech Pharma.
When does the fiscal year end for Midatech Pharma?
Midatech Pharma's fiscal year ends in December.
Where is Midatech Pharma based?
Midatech Pharma's address is: Oddfellows House, Cardiff, United Kingdom, CF24 0AA
What is Midatech Pharma's ISIN number?
Midatech Pharma's international securities identification number is: US59564R3021
What is Midatech Pharma's CUSIP number?
Midatech Pharma's Committee on Uniform Securities Identification Procedures number is: 59564R104

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site